Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Mitterbauer, M; Neumeister, P; Kalhs, P; Brugger, S; Fischer, G; Dieckmann, K; Hoecker, P; Hinterberger, W; Linkesch, W; Simonitsch, I; Jaeger, U; Lechner, K; Mannhalter, C; Mitterbauer, G; Greinix, HT.
Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma.
Leukemia. 2001; 15(4):635-641
Doi: 10.1038/sj.leu.2402053
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Greinix Hildegard
- Linkesch Werner
- Neumeister Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- From 1987 to 1999 35 patients with poor prognosis non-Hodgkin's lymphoma (NHL) underwent allogeneic stem cell transplantation (SCT) at the University Hospitals of Vienna and Graz. Initial biopsy specimens were reclassified according to the Revised European-American Classification of Lymphoid Neoplasms (REAL). All patients surviving 28 days engrafted. Twenty-eight of them (93%) attained clinical remission. At the last follow-up 14 patients were alive and disease-free at a median of 5.0 (range, 2.3-12.9) years after allogeneic SCT. The actuarial overall survival is 35%. Five patients relapsed 1.8 to 27.6 months after transplant, the probability of relapse is 23%. Of the 21 deaths following SCT, seven were due to relapse/refractory disease and 14 due to transplant-related causes. The probability of treatment-related mortality is 48%. After SCT, minimal residual disease (MRD) was monitored by polymerase chain reaction (PCR) in seven patients with a BCL-2/IgH translocation and in 13 with a clonal immunoglobulin heavy chain (IgH) rearrangement. All 20 patients attained clinical remission rapidly and converted to PCR negativity. In the follow-up nine of these patients are in long-term clinical and molecular remission, six PCR-negative patients died of transplant-related causes and five patients relapsed. In summary, allogeneic stem cell transplantation has a curative potential for patients with refractory and recurrent non-Hodgkin's lymphoma. In our series long-term disease-free survival was associated with molecular disease eradication after SCT. Treatment-related mortality rate was high, thus earlier referral of selected patients to allogeneic SCT should be considered.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Female -
- Gene Rearrangement -
- Genes, Immunoglobulin -
- Genes, bcl-2 -
- Graft vs Host Disease - etiology
- Hematopoietic Stem Cell Transplantation -
- Humans -
- Immunoglobulin Heavy Chains - genetics
- Lymphoma, Non-Hodgkin - genetics Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - therapy
- Male -
- Middle Aged -
- Polymerase Chain Reaction -
- Prognosis -
- Transplantation, Homologous -
- Find related publications in this database (Keywords)
- alloSCT
- non-Hodgkin's lymphoma
- polymerase chain reaction
- BCL2/IgH
- immunoglobulin rearrangement